Hangzhou Tigermed Consulting (03347): As of June 12, a total of 9.0588 million A-shares have been repurchased.
Tiger Pharmaceuticals (03347) announced that as of June 12, 2026, the company has repurchased 9.0588 million shares through its special securities account for share buyback through centralized bidding trading, accounting for 1.0521% of the company's current total share capital and 1.2276% of the company's current A-share total share capital. The highest transaction price was 39.96 yuan per share, the lowest transaction price was 38.22 yuan per share, and the total transaction amount was 357 million yuan (excluding transaction costs). This repurchase is in compliance with the company's share repurchase program and relevant laws and regulations.
Hangzhou Tigermed Consulting (03347) announced that as of June 12, 2026, the company had repurchased a total of 9.0588 million shares through its special securities account for share repurchases via centralized competitive trading. This represents 1.0521% of the company's current total share capital and 1.2276% of the company's current A-share total share capital. The highest transaction price was 39.96 yuan per share, the lowest transaction price was 38.22 yuan per share, and the total transaction amount was 357 million yuan (excluding transaction fees). This repurchase complies with the company's share repurchase plan and relevant laws and regulations.
Related Articles
Buying low on Shenzhen Hepalink Pharmaceutical Group (09989) for two consecutive months, will the Hong Kong Stock Connect funds soon witness the reversal of the heparin cycle?
New Stock News | Leading supply chain company Andes Zhilian's Hong Kong IPO prospectus updated, achieving double high increase in revenue and net profit.
How strong is the demand for SpaceX (SPCX.US) IPO? Oversubscribed subscriptions, "greenshoe" exemption from commission, and options expected to open next week!
Buying low on Shenzhen Hepalink Pharmaceutical Group (09989) for two consecutive months, will the Hong Kong Stock Connect funds soon witness the reversal of the heparin cycle?
New Stock News | Leading supply chain company Andes Zhilian's Hong Kong IPO prospectus updated, achieving double high increase in revenue and net profit.
How strong is the demand for SpaceX (SPCX.US) IPO? Oversubscribed subscriptions, "greenshoe" exemption from commission, and options expected to open next week!
RECOMMEND
